

eISBN: 978-1-68108-251-6

ISBN: 978-1-68108-252-3

ISSN: 2451-8395

eISSN: 1879-6656

Frontiers in Anti-Cancer Drug Discovery

Volume 7

Editors:

Atta-ur-Rahman, *FRS*

M. Iqbal Choudhary

Bentham  Books

Frontiers in Anti-Cancer Drug Discovery

(Volume 7)

Edited By

Atta-ur-Rahman, *FRS*

Kings College

University of Cambridge

Cambridge

UK

&

M. Iqbal Choudhary

H.E.J. Research Institute of Chemistry

International Center for Chemical and Biological Sciences

University of Karachi

Karachi

Pakistan

Frontiers in Anti-Cancer Drug Discovery

Volume # 7

Editors: Prof. Atta-ur-Rahman, *FRS* and Prof. M. Iqbal Choudhary

eISSN (Online): 1879-6656

ISSN (Print): 2451-8395

eISBN (Online): 978-1-68108-251-6

ISBN (Print): 978-1-68108-252-3

© 2016, Bentham eBooks imprint.

Published by Bentham Science Publishers – Sharjah, UAE. All Rights Reserved.

First published in 2016.

BENTHAM SCIENCE PUBLISHERS LTD.

End User License Agreement (for non-institutional, personal use)

This is an agreement between you and Bentham Science Publishers Ltd. Please read this License Agreement carefully before using the ebook/echapter/ejournal (“**Work**”). Your use of the Work constitutes your agreement to the terms and conditions set forth in this License Agreement. If you do not agree to these terms and conditions then you should not use the Work.

Bentham Science Publishers agrees to grant you a non-exclusive, non-transferable limited license to use the Work subject to and in accordance with the following terms and conditions. This License Agreement is for non-library, personal use only. For a library / institutional / multi user license in respect of the Work, please contact: permission@benthamscience.org.

Usage Rules:

1. All rights reserved: The Work is the subject of copyright and Bentham Science Publishers either owns the Work (and the copyright in it) or is licensed to distribute the Work. You shall not copy, reproduce, modify, remove, delete, augment, add to, publish, transmit, sell, resell, create derivative works from, or in any way exploit the Work or make the Work available for others to do any of the same, in any form or by any means, in whole or in part, in each case without the prior written permission of Bentham Science Publishers, unless stated otherwise in this License Agreement.
2. You may download a copy of the Work on one occasion to one personal computer (including tablet, laptop, desktop, or other such devices). You may make one back-up copy of the Work to avoid losing it. The following DRM (Digital Rights Management) policy may also be applicable to the Work at Bentham Science Publishers’ election, acting in its sole discretion:
 - 25 ‘copy’ commands can be executed every 7 days in respect of the Work. The text selected for copying cannot extend to more than a single page. Each time a text ‘copy’ command is executed, irrespective of whether the text selection is made from within one page or from separate pages, it will be considered as a separate / individual ‘copy’ command.
 - 25 pages only from the Work can be printed every 7 days.
3. The unauthorised use or distribution of copyrighted or other proprietary content is illegal and could subject you to liability for substantial money damages. You will be liable for any damage resulting from your misuse of the Work or any violation of this License Agreement, including any infringement by you of copyrights or proprietary rights.

Disclaimer:

Bentham Science Publishers does not guarantee that the information in the Work is error-free, or warrant that it will meet your requirements or that access to the Work will be uninterrupted or error-free. The Work is provided "as is" without warranty of any kind, either express or implied or statutory, including, without limitation, implied warranties of merchantability and fitness for a particular purpose. The entire risk as to the results and performance of the Work is assumed by you. No responsibility is assumed by Bentham Science Publishers, its staff, editors and/or authors for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products instruction,

advertisements or ideas contained in the Work.

Limitation of Liability:

In no event will Bentham Science Publishers, its staff, editors and/or authors, be liable for any damages, including, without limitation, special, incidental and/or consequential damages and/or damages for lost data and/or profits arising out of (whether directly or indirectly) the use or inability to use the Work. The entire liability of Bentham Science Publishers shall be limited to the amount actually paid by you for the Work.

General:

1. Any dispute or claim arising out of or in connection with this License Agreement or the Work (including non-contractual disputes or claims) will be governed by and construed in accordance with the laws of the U.A.E. as applied in the Emirate of Dubai. Each party agrees that the courts of the Emirate of Dubai shall have exclusive jurisdiction to settle any dispute or claim arising out of or in connection with this License Agreement or the Work (including non-contractual disputes or claims).
2. Your rights under this License Agreement will automatically terminate without notice and without the need for a court order if at any point you breach any terms of this License Agreement. In no event will any delay or failure by Bentham Science Publishers in enforcing your compliance with this License Agreement constitute a waiver of any of its rights.
3. You acknowledge that you have read this License Agreement, and agree to be bound by its terms and conditions. To the extent that any other terms and conditions presented on any website of Bentham Science Publishers conflict with, or are inconsistent with, the terms and conditions set out in this License Agreement, you acknowledge that the terms and conditions set out in this License Agreement shall prevail.

Bentham Science Publishers Ltd.

Executive Suite Y - 2
PO Box 7917, Saif Zone
Sharjah, U.A.E.
Email: subscriptions@benthamscience.org



CONTENTS

PREFACE	i
LIST OF CONTRIBUTORS	iv
CHAPTER 1 MALIGNANT PLEURAL MESOTHELIOMA (MPM): LATENT DISEASE	3
<i>M. Genovés Crespo, F.J. Callejas González, R.D. García Ángel, W. Mayoris Almonte and F.J. Agustín Martínez</i>	
INTRODUCTION	4
Historical Facts and Etiology	4
Epidemiology	8
Pathogenesis	8
Molecular Biology [33]	9
Clinical Findings	12
Diagnosis	13
<i>Imaging Tests</i>	13
<i>Pleural Fluid Cytology</i>	14
<i>Pleural Biopsy and Thoracoscopy</i>	15
<i>Histology of Malignant Pleural Mesothelioma</i>	17
<i>Monoclonal Antibodies</i>	20
<i>Biomarkers in the Diagnosis of Malignant Mesothelioma</i>	22
Prognostic Factors	27
<i>Clinic Pathological Prognostic Factors</i>	29
<i>Genetic Prognostics Factors</i>	31
<i>Prognostic Factors of the Molecular Pathway</i>	32
MPM Staging	34
Treatment	37
<i>Pretreatment Evaluation</i>	37
<i>Chemotherapy</i>	38
<i>Intraoperative Hyperthermic Chemotherapy</i>	39
<i>Radiotherapy</i>	39
<i>Surgical Treatment</i>	40
<i>Extrapleural Pneumonectomy</i>	41
<i>Pleurectomy/Decortication</i>	43
<i>Pleurodesis</i>	44
New and Future Therapies	44
Inducing Angiogenesis	52
<i>Evading Growth Suppressors</i>	55
<i>Enabling Replicative Immortality and Tumor Promoting Inflammation</i>	56
<i>Activation of Invasion and Metastasis</i>	56
Antimesothelin Antibodies	57
Immunotoxin SS1P	58
Resisting Cell Death	58
<i>Avoiding Immune Destruction</i>	59
Cytotoxic T Lymphocyte Antigen-4	60
Receptor-1 Programmed Death	60
<i>Genome Instability, Mutations and Epigenetic Dysregulation</i>	61
<i>Deregulating Cellular Metabolism</i>	63
<i>Vaccines and Immunotherapy</i>	64
<i>Dendritic Cells Vaccine</i>	65
<i>Photodynamic Therapy</i>	66

<i>Iodine-povidone Lavage (Betadine®)</i>	66
<i>Cryotherapy</i>	66
CONCLUSION	66
CONFLICT OF INTEREST	67
ACKNOWLEDGEMENTS	67
REFERENCES	67

CHAPTER 2 COLORECTAL CANCER THERAPEUTIC APPROACHES: FROM CLASSICAL DRUGS TO NEW NANOPARTICLES 93

<i>Giulia Cazzanelli, Tiago Moreira, Suellen Ferro, João Azevedo-Silva, Eugénia Nogueira and Ana Preto</i>	
OVERVIEW ON COLORECTAL CANCER	94
Epidemiology and Risk Factors of Colorectal Cancer	94
Hallmarks of Colorectal Cancer	96
CURRENT THERAPEUTIC APPROACHES TO COLORECTAL CANCER	101
Cytotoxic Agents: The Classical Approach in Colorectal Cancer Therapy	102
<i>5-Fluorouracil</i>	103
<i>Leucovorin</i>	106
<i>Irinotecan</i>	108
<i>Oxaliplatin</i>	109
Signaling Pathways Inhibitors - New Molecular Targeted Therapy for Colorectal Cancer	112
<i>Epidermal Growth Factor Receptor and Downstream Signaling Pathways</i>	112
<i>Other Growth Factor Receptors Relevant for Colorectal Carcinoma Progression</i>	122
<i>Increasing Apoptosis Signaling: A New Colorectal Cancer Therapeutic Approach</i>	125
THE IMPLICATION OF TARGETING THE METABOLISM IN COLORECTAL CANCER THERAPY	127
Colorectal Cancer Prevention: A Question of Metabolic Equilibrium	128
Metabolic Alterations in Colorectal Cancer: Therapeutic Strategies	130
<i>Targeting Metabolism for Colorectal Cancer Therapy</i>	130
<i>Targeting Lactate Export for Colorectal Cancer Therapy</i>	135
USE OF NANOPARTICLES IN COLORECTAL CANCER THERAPY: PRESENT OR FUTURE?	136
Nanoparticles in Colorectal Cancer Therapy	137
<i>Stealth Nanoparticles</i>	139
<i>Colorectal Cancer Targeted Nanoparticles</i>	140
CONCLUSION	143
CONFLICT OF INTEREST	143
ACKNOWLEDGEMENTS	143
REFERENCES	144

CHAPTER 3 THE LATEST DEVELOPMENTS IN ANTI-PANCREATIC CANCER DRUGS: A PROMISING FUTURE AHEAD 174

<i>Salih Samo, Muhammed Sherid, Sidhartha Tulachan, Humberto Sifuentes and Subbaramiah Sridhar</i>	
INTRODUCTION	174
Origin of Pancreatic Cancer Cells	176
Molecular Biology of Pancreatic Cancer	176
Cellular Metabolism in Pancreatic Cancer	178
Pancreatic Cancer Components	179
Immunomodulation in Pancreatic Cancer	180
Pancreatic Cancer Staging and Survival	181
MANAGEMENT OF PANCREATIC CANCER BASED ON STAGING	182
Stage I or II (Surgically Resectable Tumors)	182
Stage III (Locally Advanced, Unresectable Tumors)	183
Stage IV (Metastatic Tumors)	183

TREATMENT REGIMENS IN PANCREATIC CANCER	184
First Line Therapy	184
<i>Gemcitabine</i>	184
<i>Gemcitabine (Fixed-Dose Infusion)</i>	185
<i>Gemcitabine Plus Oxaliplatin</i>	185
<i>Gemcitabine Plus Cisplatin</i>	185
<i>Gemcitabine Plus Erlotinib</i>	185
<i>Gemcitabine Plus Capecitabine</i>	186
<i>FOLFIRINOX (Oxaliplatin, Irinotecan, Fluorouracil, and Leucovorin)</i>	186
<i>Nanoparticle Albumin-Bound Paclitaxel (Nab-Paclitaxel) Plus Gemcitabine</i>	187
Second Line Therapy	187
<i>Modified FOLFOX (Fluorouracil, Leucovorin, and Oxaliplatin) and Modified FOLFIRI.3 (Fluorouracil, Leucovorin, and Irinotecan)</i>	187
<i>Oxaliplatin Plus Capecitabine</i>	188
<i>Capecitabine Plus Erlotinib</i>	188
STRATEGIC TARGETS AND NOVEL AGENTS IN PANCREATIC CANCER-FUTURE DIRECTIONS	188
Hedgehog Pathway	188
Death Receptor (DR5)	190
Mucin-1	190
C-kit, PDGFR, FGFR	190
MEK (Mitogen-Activated Protein Kinase/Extracellular Signal-Regulated Kinase)	191
Src	191
RAS	191
PSCA (Prostate Stem-Cell Antigen)	191
Mesothelin	192
TNF- α (Tumor Necrosis Factor- α)	192
Cationic Liposome Encapsulated Paclitaxel (EndoTAGTM-1)	192
IGF-IR (Type I Insulin-like Growth Factor Receptor)	193
CONCLUSION	193
CONFLICT OF INTEREST	193
ACKNOWLEDGEMENTS	193
REFERENCES	194

CHAPTER 4 ADJUVANT ENDOCRINE THERAPY FOR EARLY BREAST CANCER 201

Georgios M. Iatrakis

INTRODUCTION	202
Tamoxifen	204
<i>Cardiovascular System</i>	208
<i>Central Nervous System</i>	209
<i>Dermatologic</i>	209
<i>Endocrine & Metabolic</i>	209
<i>Gastrointestinal System</i>	209
<i>Genitourinary System</i>	209
<i>Renal</i>	210
<i>Neuromuscular & Skeletal System</i>	210
<i>Respiratory System</i>	210
<i>Miscellaneous</i>	210
Ovarian Suppression	210
Aromatase Inhibitors	212
Anastrozole	216
Letrozole	217

Exemestane	218
Future Perspectives	219
CONCLUSION	220
CONFLICT OF INTEREST	220
ACKNOWLEDGEMENTS	220
REFERENCES	220

CHAPTER 5 CYCLIN E AND ITS POTENTIAL USE FOR LIVER CANCER PROGNOSIS AND THERAPY 228

Nikki P. Lee

LIMITATIONS OF CURRENT LIVER CANCER MANAGEMENT	228
Deregulation of Cell Cycle in Tumorigenesis	229
Cyclin E, A Cell Cycle Molecule Regulating G1 to S Phase Transition	230
Different Forms of Cyclin E and Their Involvements in Tumorigenesis	231
The Role of Retinoblastoma-E2F Transcriptional Factor Network (A Downstream Mechanism of Cyclin E) in Tumorigenesis	233
Prognostic Value of Cyclin E in HCC	235
Cyclin E as a Therapeutic Target for HCC	236
CONCLUSION AND FUTURE PERSPECTIVES	237
CONFLICT OF INTEREST	238
ACKNOWLEDGEMENTS	238
REFERENCES	238

SUBJECT INDEX 243

PREFACE

Cancers are major causes of death today. Cancer incidents are far greater now than at any time in human history. Despite vigorous research in the fields of cellular and molecular biology of cancer cells, cancer genetics, cancer related proteomics, transcriptomics, and metabolomics, as well as medicinal chemistry, the successful treatment of various cancers has met with limited success. The main issue has been our inability to translate most of the basic research discoveries into medicines that can substantially improve the treatment of many cancers. The problems are even more complex in cancer forms which are either very rare or highly heterogeneous. Cancer treatment thus is a grand challenge of our times. Scientists, and health care professionals in the academia, government, and in industries are striving to meet this mega challenge of the 21st century, apparent from the huge number of basic and epidemiological research publications. This has created a need of a focused book series, based on reviews of current literature by leading experts. The eBook series “*Frontiers in Anti-Cancer Drug Discovery*” is a humble effort to cater to this need.

The 7th volume of this internationally recognized books series comprises five comprehensive reviews, written by leading practitioners in this field. Each review is focused on certain important aspects of anti-cancer drug discovery and development, including identification of new molecular targets, and outcomes of pre-clinical and clinical studies on new drugs, and combination therapies.

Callejas González *et al.* have reviewed recent pre-clinical and clinical studies on various drugs against malignant pleural mesothelioma (MPM). It is a rare but highly aggressive cancer of the linings of the lungs and the chest wall, known as the Pleural mesothelioma, caused by exposure to asbestos. Apart from surgical removal of the affected part, combination of chemotherapy, such as pemetrexed and cisplatin, is known to increase the median survival rate in MPM patients. The authors have extensively reviewed the results of various pre-clinical and clinical studies conducted on new and known combinations of chemotherapeutic agents against MPM. This includes mesothelin specific antibody and toxin therapies, gene therapy, interleukin-4 receptor toxins, dendritic cell vaccines, *etc.* The emphasis has been on improving the evolution of the disease and development of better clinical models for treatment.

The review contributed by Preto *et al.* gives a comprehensive account of the various therapeutic options available for the treatment of highly malignant and complex colorectal cancer (CRC). Starting from a detailed introduction of the disease, the authors have systematically reviewed the issues related to the conventional chemotherapeutic agents, such as specific EGFR signalling antagonists, including emerging resistance. This is followed by

an interesting commentary of anti-cancer properties of short-chain fatty acids (SCFA), produced by symbiotic bacteria in colorectal environment. The potential of SCFA in the prevention and treatment of CRC is an interesting area of research. The potential of new class of metabolic inhibitors of glycolytic metabolism in colorectal cancer cells has also been discussed as new therapeutic adjuvants, in combination with other therapies. The review ends with a critical analysis of the literature on the development and use of nanoparticles for cancer therapies, for reducing their adverse effects.

Pancreatic cancer has a poor prognosis, even if diagnosed early. It spreads rapidly and is rarely detected in its early phases, making it a leading cause of cancer death. Surgical removal of cancerous pancreas, before metastases, is the most practiced treatment regimen. Chemotherapy against pancreatic cancer, though used frequently, has many limitations. Sridhar *et al.* have reviewed the most recent R&D on emerging new therapies against pancreatic cancers. The new drugs specifically target various growth factors and signalling molecules, including epidermal growth factors, and hedgehog signalling pathway. The pre-clinical and clinical outcomes of these drugs are presented in this article.

The review by Georgios M. Iatrakis is focussed on the role of adjuvant endocrine therapies in early breast cancer (BC) treatment. Endocrine adjuvant therapy plays an important role in the prevention, recurrence and treatment of hormone receptor-positive breast cancer. It has been shown to reduce the risk of recurrence and death from breast cancer. Tamoxifen (Tx) is a selective estrogen receptor modulator. Recent clinical trials on prolonged (10 years) Tx treatment of BC in certain categories of BC patients has led to significant reduction in mortality due to recurrence. Similarly, treatment with aromatase inhibitors (AIs), such as anastrozole, exemestane and letrozole has shown to have clinical outcome, often superior than the Tx. The author discuss in greater length the comparative advantage of the use of Tx *versus* AIs in various types of breast cancers.

Cyclin E is a member of the cyclin family of proteins. It binds to G₁ phase Cdk2, which is required for transition from the G₁ to S phase of the cell cycle that regulates cell division. At the molecular level, liver cancer is characterised by a disruption of cell cycle regulation through many molecular mechanisms, including over-expression of cyclins (cyclins D, A, E, and B). The review contributed by Nikki P. Lee presents the role of cyclin E in the regulation of cell cycle during liver cancer, focusing mainly on hepatocellular carcinoma (HCC). The potential use of cyclin E for HCC prognosis and treatment is also highlighted and discussed.

In the end, we wish to express our gratitude to the authors of the above cited reviews for their excellent scholarly contributions for the 7th volume of this eBook series. We also appreciate the efforts of the entire team of the Bentham Science Publishers for efficient processing. The skills and efforts of Ms. Fariya Zulfiqar (Assistant Manager Publications), Mr. Shehzad Naqvi (Senior Manager Publications) and the leadership of Mr. Mahmood Alam (Director

Publications) are greatly appreciated. We also hope that like the previous volumes, the current volume will also receive wide readership and recognition.

Prof. Atta-ur-Rahman, *FRS*

Kings College
University of Cambridge
UK

Prof. M. Iqbal Choudhary

H.E.J. Research Institute of Chemistry
International Center for Chemical and Biological Sciences
University of Karachi
Pakistan

List of Contributors

- Agustín Martínez F.J** Pneumology Department, Albacete University Hospital, Albacete, Spain
- Ana Preto** Centre of Molecular and Environmental Biology (CBMA), Department of Biology, University of Minho, Campus de Gualtar, Braga 4710-057, Portugal
- Callejas González F.J** Pneumology Department, Albacete University Hospital, Albacete, Spain
- Eugénia Nogueira** Centre of Molecular and Environmental Biology (CBMA), Department of Biology, University of Minho, Campus de Gualtar, Braga 4710-057, Portugal
- García Ángel R.D** Pathology Department, Albacete University Hospital, Albacete, Spain
- Genovés Crespo M** Thoracic Surgery Department, Albacete University Hospital, Albacete, Spain
- Georgios M. Iatrakis** Technological Educational Institute of Athens, Athens, Greece
- Giulia Cazzanelli** Centre of Molecular and Environmental Biology (CBMA), Department of Biology, University of Minho, Campus de Gualtar, Braga 4710-057, Portugal
- Humberto Sifuentes** Section of Gastroenterology and Hepatology, Georgia Regents University, Augusta, GA, USA
- João Azevedo-Silva** Centre of Molecular and Environmental Biology (CBMA), Department of Biology, University of Minho, Campus de Gualtar, Braga 4710-057, Portugal
- Mayoris Almonte W** Pneumology Department, Albacete University Hospital, Albacete, Spain
- Muhammed Sherid** Section of Gastroenterology and Hepatology, Georgia Regents University, Augusta, GA, USA
- Nikki P. Lee** Department of Surgery, The University of Hong Kong, Hong Kong, China, and Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Zhejiang University, 310003 Hangzhou, China
- Salih Samo** Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
- Sidhartha Tulachan** Section of Gastroenterology and Hepatology, Georgia Regents University, Augusta, GA, USA
- Subbaramiah Sridhar** Section of Gastroenterology and Hepatology, Georgia Regents University, Augusta, GA, USA
- Suellen Ferro** Centre of Molecular and Environmental Biology (CBMA), Department of Biology, University of Minho, Campus de Gualtar, Braga 4710-057, Portugal
- Tiago Moreira** Centre of Molecular and Environmental Biology (CBMA), Department of Biology, University of Minho, Campus de Gualtar, Braga 4710-057, Portugal

Malignant Pleural Mesothelioma (MPM): Latent Disease

M. Genovés Crespo¹, F.J. Callejas González^{2,*}, R.D. García Ángel³, W. Mayoris Almonte² and F.J. Agustín Martínez²

¹ Thoracic Surgery Department, Albacete University Hospital, Albacete, Spain

² Pneumology Department, Albacete University Hospital, Albacete, Spain

³ Pathology Department, Albacete University Hospital, Albacete, Spain

Abstract: Malignant pleural mesothelioma (MPM) is a cancer with aggressive nature and poor prognosis (the median survival ranges from 9-18 months). The worldwide incidence of this disease is increasing, with 2180 estimated new cases diagnosed in the United States in 2013. Despite the apparent benefits offered by the multimodal approach (a combination of surgery, chemotherapy -cisplatin/ pemetrexed- and radiotherapy), survival remains poor. As a consequence, multiple therapies aiming to improve the evolution of the disease are under investigation. In this chapter, we will summarize some of the new preclinical and early clinical developments in the treatment of MPM, which include mesothelin specific antibody and toxin therapies, gene therapy, interleukin-4 (IL-4) receptor toxins and dendritic cell vaccines, among others.

Keywords: Activation of invasion, Activation of metastasis, Angiogenesis induction, Avoiding immune destruction, Cancer therapy, Chemotherapy, Cryotherapy, Dendritic cells vaccine, Deregulating cellular metabolism, Enabling replicative immortality, Evading growth suppressors, Genome instability, mutations and epigenetic dysregulation, Intraoperative hyperthermic chemotherapy, Iodine-povidone lavage, Malignant pleural mesothelioma (MPM), Photodynamic therapy, Radiotherapy, Resisting cell death, Surgical treatment,

* Corresponding author Francisco Javier Callejas González: Department of Thoracic Surgery and Department of Pulmonology. The Albacete University Hospital Complex, Albacete, Spain; Tel: +34 620713404; Fax: 34 967598002; Email: marta_genoves@hotmail.es

Sustaining proliferative signaling, Tumor promoting inflammation, Vaccines and immunotherapy.

INTRODUCTION

Malignant pleural mesothelioma (MPM) is a term used to refer to aggressive tumors involving mesothelial cells. These cells normally cover body cavities, especially pleura, peritoneum, pericardium and testicles. Over 90% of cases of mesothelioma occur in the pleura, compared to 4-7% appearing in the peritoneum and less than 1% in the pericardium and testicles [1].

MPM is a malignancy with low prevalence, highly variable clinical presentation and often requires an individualized approach. As a result, conclusions must usually be extracted from small series, retrospectives, specific studies and subjective experiences.

Prognosis of MPM is poor due to the difficulty in establishing an early stage diagnosis, as a result of its rapid progression, high capacity of invasion and the lack of effective treatments [1].

Historical Facts and Etiology

MPM is located in the pleura in 90% of cases, the visceral pleura in 80% and the parietal pleura in 20%. Its association with asbestos is well established since the 50s [2]. In approximately 80% of mesothelioma cases, there is a causal link with occupational exposure to asbestos, involving a wide range of occupations [2].

MPM has been considered an occupational illness. Historically, occupations related to this disease have been categorized into three different groups depending on exposure type. Initially, it was mainly diagnosed in mine and mill workers who were directly exposed to asbestos. Secondly, MPM was diagnosed in plumbers, carpenters, personal defense and insulation installers [2]. And lastly, in people living in areas with exposure to atmospheric asbestos fibers located close to asbestos mines or factories.

In addition, a dose-response relationship between cumulative exposure (high levels of exposure, duration of exposure or both) and MPM has been

demonstrated. Likewise, no threshold below which no risk of contracting the disease exists has been identified [1, 3]. Usually, patients with peritoneal mesothelioma have suffered more intense exposure than patients with pleural disease [4, 5].

The first histological description of MPM malignancy was made by *E. Wagner* in 1870. However, MPM was not associated with asbestos until 1960, as a result of the industrial development occurred during *World War II*, which led to a global increase in the use of this mineral. As a result of his work in South Africa –a country extracting the three commercial types of asbestos–, *JC Wagner et al.* described MPM as a disease with a long latency period affecting mainly miners and mill workers, especially when exposed to crocidolite [6].

Musk *et al.* have conducted a study in Wittenoom (Western Australia) with 7000 mineworkers that had been exposed to blue asbestos (crocidolite) between 1943 and 1966 [7]. At the end of 1986, 94 cases of MPM had been identified, while between 1987 and 2015, there are 692 new documented cases. This industrial disaster is considered the worst of its kind in the history of Australia [7].

Asbestos is the common name given to a group of natural silicates which can be found in soil and can be classified into two types:

- Serpentine (chrysotile or “white asbestos”)
- Amphibole (crocidolite “blue asbestos”), tremolite, amosite “brown asbestos”), anthophyllite and actinolite).

The type of asbestos fiber is a critical risk factor involved in the development of MPM. Serpentine fibers are large, flexible and curly, and they tend to stay in the conducting airways of the respiratory tract. In contrast, amphibole fibers tend to be short, straight and rigid, and move into the lymphatic system of the lung parenchyma, accumulating in the interstitial spaces and the subpleural region. Amphibole fibers, especially crocidolite, are clearly related to MPM; while chrysotile has been more related to lung cancer [8, 9].

The association between MPM and erionite is also known. Erionite is a natural contaminant of the soil that can be found in various regions of the world,

Colorectal Cancer Therapeutic Approaches: From Classical Drugs to New Nanoparticles

Giulia Cazzanelli, Tiago Moreira, Suellen Ferro, João Azevedo-Silva, Eugénia Nogueira and Ana Preto*

Centre of Molecular and Environmental Biology (CBMA), Department of Biology, University of Minho, Campus de Gualtar, Braga 4710-057, Portugal

Abstract: Colorectal cancer (CRC) is the second most commonly diagnosed cancer and the third leading cause of cancer related death in the world. Epidemiological studies show that CRC incidence and mortality vary substantially across different regions of the world. CRC is a multifactorial disease process, in which may intervene familial and hereditary factors, as well as age, environmental causes, lifestyle-related risk factors, namely diet and inflammatory conditions of the digestive tract. Several genetic alterations have been associated to the process of colon carcinogenesis, namely epidermal growth factor receptor (EGFR) activation, BRAF and KRAS mutations among others.

Many options for CRC treatment are available, including surgery, chemotherapy, and radiation. Herein, we will describe the main classical drugs used in CRC chemotherapy, such as 5-Fluoracil, Leucovorin, Irinotecan, and Oxaliplatin. Recent anti-CRC therapies are now targeting specifically signaling pathways implicated in colorectal carcinogenesis, such as EGFR (Cetuximab, Matuzumab, Erlotinib, Panitumumab), which appears highly overexpressed in most CRC patient cases. However, this approach is limited by resistance conferred by the activation of mutations in EGFR downstream signaling pathways. As a result, an increasing number of specific components of these pathways have been targeted in order to overcome the resistance to conventional EGFR-targeted therapies. Despite the recent advances, conventional chemotherapy remains unable to improve the prognosis of advanced or recurrent CRC.

* **Corresponding author Ana Preto:** Department of Biology, University of Minho, Campus de Gualtar, 4710-057 Braga, Portugal; Tel: +351 253 601524; Fax: +351 253 678980; Email: apreto@bio.uminho.pt

In colorectal environment, there is a symbiotic relationship between intestinal cells and bacteria from the diet. Indeed, colonocytes metabolize short-chain fatty acids (SCFA), byproducts of anaerobic bacterial fermentation of dietary fiber. These SCFAs play a significant role in maintaining the normal physiological functions of the colon mucosa, but they also have strong anti-tumorigenic properties, such as reduction of cancer cell proliferation and differentiation and stimulation of apoptosis in CRC cells. Here we discuss the exploitation of anti-apoptotic features of SCFA in the development of new prevention and therapeutic approaches.

Changes in cellular metabolism are a crucial hallmark of cancer and CRCs were shown to present a glycolytic phenotype even in the presence of oxygen, phenomenon commonly designated as the 'Warburg effect'. We will also discuss the use of metabolic inhibitors as new therapeutic adjuvants *per se* or in combination with other therapies.

To reduce off-target associated adverse effects and achieve targeted drug delivery in cancer therapy, nanomedicine is emerging as a promising strategy. The transport of classical drugs by nanoparticles has shown great promise in improving drug distribution and bioavailability, increasing the anticancer molecules concentration at the cancer tissue, providing optimal drug delivery, and minimizing drug toxicity. Additionally, targeting CRC cells may be improved by incorporating ligands for cancer-specific surface receptors such as EGFR, bringing new opportunities in the treatment of patients with CRC.

Keywords: Bevacizumab, Cetuximab, Classical chemotherapy, Colorectal cancer, 5-Fluoracil, Irinotecan, Metabolic targets, Nanoparticles, Oxaliplatin, Panitumumab, Target therapy.

OVERVIEW ON COLORECTAL CANCER

Epidemiology and Risk Factors of Colorectal Cancer

Colorectal cancer (CRC) is one of the most common cancers worldwide, accounting for over 1 million cases and about half a million deaths annually [1, 2]. CRC is the third most frequent cancer in men, after lung and prostate cancers, and it is the second most frequent cancer in women after breast cancer [3].

Epidemiological studies show that CRC incidence and mortality vary substantially across regions of the world [4 - 6]. The highest incidence is in Western Europe,

North America, Australia and New Zealand [6]. In Europe, CRC is the second cause of death among all cancer types in both genders [3], with ~446.000 new cases arising each year [3, 7]. The incidence rate of CRC is low up to the age of 45-50 years [3], but progressively increases with age. Furthermore, the incidence is higher in the Western world, especially among populations that adopt Western-style diets [1, 4, 8, 9].

CRC is a multifactorial disease process, in which may intervene familial and hereditary factors, age, environmental lifestyle-related risk factors (diet, physical inactivity, obesity, smoking and alcohol consumption), as well as inflammatory conditions of the digestive tract [4].

Approximately 20% of all CRC cases can be attributed to heritable gene variations. In this case, some patients are predisposed to develop CRC: patients with hereditary conditions such as familial adenomatous polyposis (FAP), hereditary non-polyposis CRC and ulcerative colitis [3]. However, the largest fraction of CRC cases is sporadic and linked to environmental causes [3, 4, 8, 9]. The most common risk factors of non-hereditary CRC include upper-middle socioeconomic status and dietary regimens rich in proteins, especially those with high intake of red meat, processed meat and animal fats and usually poor in unrefined cereals and fibers [2, 4, 8]. The association between high intake of red and processed meat and CRC risk has been associated with the content of the meat and the compounds generated by the cooking process (e.g. N-nitrous compounds) [8]. These factors can affect the large intestine mucosa with genotoxicity and metabolic alterations that contribute to colon carcinogenesis [6, 8]. As for smoking tobacco it acts on the intestinal mucosa through the production of carcinogenic agents such as acetaldehyde, benzopyrenes, aromatic amines and N-nitrosamines and by increasing the risk of microsatellite instability [4, 6]. Excessive alcohol consumption has been showed to accelerate CRC initiation and progression by inflammation and epigenetics [4].

On the other hand, CRC may be easily prevented with a dietary fiber consumption [10]. Many of the benefits derived from fiber consumption can be attributed to the anaerobic bacterial fermentation of dietary fiber into short chain fatty acids (SCFAs) [10]. The three major colonic SCFAs are butyrate, propionate and

The Latest Developments in Anti-Pancreatic Cancer Drugs: *A Promising Future Ahead*

Salih Samo¹, Muhammed Sherid², Sidhartha Tulachan², Humberto Sifuentes² and Subbaramiah Sridhar^{2,*}

¹ Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA

² Section of Gastroenterology and Hepatology, Georgia Regents University, Augusta, GA, USA

Abstract: Pancreatic cancer has been increasingly diagnosed in the recent decades. Although the cornerstone treatment for pancreatic cancer is surgery, unfortunately, only 15-20% has a resectable disease at the time of initial diagnosis. Owing to the majority of patients having either locally advanced diseases or metastases, chemotherapy plays an important role in the management of pancreatic cancer. Because conventional chemotherapy has its limitations in the management of pancreatic cancer, recently developed molecular targeted therapy has emerged as an important modality of treatment of the disease. Drugs targeting growth factors such as epidermal growth factor and anti-angiogenesis have been studied and have promising results. Some of these drugs such as erlotinib have been already approved for the treatment of pancreatic cancer. Newer drugs such as those targeting hedgehog signaling pathway are now being tested. In this chapter, we will comprehensively review the current and also the latest development of anti-pancreatic cancer drugs.

Keywords: Angiogenesis, Chemotherapy, Growth factors, Molecular, Pancreatic cancer.

INTRODUCTION

The incidence of all types of pancreatic cancer, of which pancreatic adenocarcino-

* Address to Corresponding Author Subbaramiah Sridhar: Section of Gastroenterology and Hepatology, Georgia Regents University, Augusta, GA. 1120 15th Street-AD 2226, Augusta, Georgia, 30912, USA; Tel: +1-706-721-2238; Fax: +1-706-721-0331; E-mail: ssridhar@gru.edu.

ma accounts for 85%, is reported from 1-10 cases per 100,000 persons throughout the world and has remained stable over the past three decades when compared Pancreatic cancer is the disease of the to the incidence of other common solid tumors. The incidence is higher among men and in the developed countries [1, 2]. Worldwide, pancreatic cancer is the eighth leading cause of death in men and the ninth leading cause of death in women from cancer. In the United States, it is the fourth leading cause of cancer death with the estimated 36,888 deaths in 2010. In 2014, the estimated new cases of pancreatic cancer in the United States were 46,420 (23,530 in males and 22,890 in females) and estimated deaths were 39,590 (20,170 in males and 19,420 in females) [3]. Pancreatic cancer is the disease of the elderly and rarely in persons younger than 40 years (Fig. 1).




Fig. (1). Incidence of pancreatic cancer per age and gender.

The localized and potentially curable pancreatic cancer is found in less than 20%

of cases [4]. The focus of this review will be on pancreatic adenocarcinoma and the current and also the latest development of anti-pancreatic cancer drugs.

Origin of Pancreatic Cancer Cells

Tumors are largely classified by histological appearance, yet morphologic features do not necessarily predict a lineage relationship [5]. Pancreatic ductal adenocarcinoma (PDAC) has long been considered to arise from pancreatic ducts based on its morphology and the occurrence of dysplasia in putative preneoplastic ductal lesion. Mounting evidence suggests that PDAC and its noninvasive precursor lesion known as pancreatic intraepithelial neoplasia (PanIN) may be the result of acinar cell metaplasia to a ductal cell form [6 - 8]. Genetically engineered mouse models based on tissue-specific *KRAS* activation and deletion of tumor suppressor genes show that PDAC appears to arise from exocrine acinar rather than ductal cells, *via* a process of phenotypic reprogramming that is Sox9-dependent [6]. Targeting of oncogenic *KRAS* mutations to elastase and Mist1-expressing acinar cells of adult mice resulted in the spontaneous induction of PanIN lesions [7]. Similarly, conditional expression of oncogenic *KRAS* along with Notch using *Pdx1* Cre recombinase synergistically caused mature acinar cells to convert to PanIN lesions [8]. These results may imply that therapeutic targeting of signaling pathways involved in ductal reprogramming of acinar cells could prevent PDAC initiation in high-risk individuals.

Molecular Biology of Pancreatic Cancer

Pancreatic cancer is a highly heterogeneous disease with a complex tumor microenvironment [9]. The genetic and cellular heterogeneity within pancreatic tumors may account for its aggressiveness. Histologically, PanIN is a well-defined precursor of pancreatic cancer [10]. The development of minimally dysplastic epithelium (PanIN 1A) to more advanced dysplasia (PanIN 3) and eventually to invasive carcinoma is the result of sequential accumulation of molecular alterations. These molecular changes include: activation of the *KRAS2* oncogene, inactivation of the tumor suppressor gene *CDKN2A* (encodes the inhibitor of cyclin dependent kinase 4 *INK4A*), and, finally, inactivation of the tumor suppressor genes *TP53* and Deleted in Pancreatic Cancer locus 4 (*DPC4*, also

Adjuvant Endocrine Therapy for Early Breast Cancer

Georgios M. Iatrakis*

Technological Educational Institute of Athens, Athens, Greece

Abstract: Hormone receptor (HR) positive breast cancers (BCs) represent the vast majority of BCs with estrogen receptor (ER)+ and/or progesterone receptor+ BCs comprising the vast majority of all cases. Tamoxifen (Tx) is a selective estrogen receptor modulator that is mainly indicated for premenopausal women with HR+ BCs (as monotherapy), resulting in a significant reduction of BC mortality. The "classical" duration of Tx therapy was 5 years. However, the results of recent trials indicate that 10 years of adjuvant Tx reduces further BC mortality. In premenopausal women, available data suggest that ovarian suppression provides no additional benefits for women treated with adjuvant Tx with the exception of women who are at sufficient risk for recurrence to warrant adjuvant chemotherapy and who remain premenopausal. Aromatase inhibitors (AIs)-anastrozole, exemestane and letrozole-have become a useful adjuvant therapy in the management of postmenopausal patients with HR+ BCs, which proved superior to Tx. Recent guidelines recommend a 5-year course of AIs, administered as initial monotherapy or after Tx, for postmenopausal women with HR+ early BCs. In premenopausal women, it is not appropriate to administer AIs as monotherapy because the low levels of estrogen could stimulate hypothalamos-pituitary axis which could trigger the ovaries for estrogen production. Taking into account the superiority of AIs to Tx, a logical hypothesis was to use AIs in premenopausal women after inducing a menopausal status with GnRH analogues. However, the use of AIs is not generalized in premenopausal women (where Tx is beneficial) but only in high risk cases (women ≤ 35 years old, and/or large tumor, high tumor grade, involved lymph nodes, lympho-vascular invasion, high recurrence score), where exemestane proved beneficial.

* **Corresponding author Georgios Iatrakis:** Technological Educational Institute of Athens, Athens, Greece; Tel: +30 6944816582; Fax: +30 2106611178; E-mail: giatrakis@teiath.gr.

Keywords: Adjuvant endocrine therapy, Anastrozole, Aromatase inhibitors, Early breast cancer, Exemestane, GnRH analogues, Letrozole, Tamoxifen.

INTRODUCTION

Breast cancer is the main cause of death in women of advanced reproductive age (40 to 49 years) [1]. Hormone receptor (HR)-positive breast cancers represent the vast majority of breast cancers with estrogen receptor (ER) positive and/or progesterone (PR) receptor-positive breast cancers comprising 60-80% of all cases [2, 3]. Actually, molecular subtypes luminal A (ER-positive and/or PR-positive, HER2-negative with low Ki-67) and luminal B (ER-positive and/or PR-positive, HER2-negative with high Ki-67 or HER2-positive) comprise the vast majority of breast cancers with a prevalence of 30-70% and 10-20% respectively. Recently, it was reported that reproductive events in adolescence have differential impact on the risk of breast cancer molecular subtypes [4].

In more detail, about $\leq 80\%$ of breast cancers are estrogen-receptor positive and about 65% of estrogen-receptor-positive breast cancers are also progesterone-receptor-positive. A small percentage of breast cancers (~2%) are estrogen-receptor-negative and progesterone-receptor-positive. While the clinical utility of ER as a predictive biomarker to identify patients likely to benefit from hormonal therapy is well-established, the added value of PR is less well-defined and controversial [5, 6]. In multivariate models considering ER status and clinicopathologic factors, routine PR testing was not associated with prognosis, as an independent factor, and its use has been questioned [5]. In fact, estrogen receptor negative/progesterone receptor positive breast cancer was not considered a reproducible subtype. On the contrary, absence of PR expression is considered a powerful, independent prognostic variable in certain cases of operable, primary breast cancer [6]. Probably, different factors can influence the lifetime risk of hormone-receptor-positive or hormone-receptor-negative breast cancer, including diet [7].

Among other systems, Allred scoring is a semi quantitative system that takes into consideration the proportion of ER positive cells (scored on a scale of 0-5) and staining intensity (scored on a scale of 0-3). The proportion and intensity are

added together to produce total scores of 0 to 8. A (total) score of 0-2 and a score of 3-8 are regarded as negative and positive respectively for ER receptors [8]. In clinical practice, another way to describe HR status is to report the percentage (%) of HR-positive cells and their staining intensity. Taking into account that manual assessment of ER status from breast tissue microscopy images is a subjective, time consuming and error prone process, automatic image analysis methods were proposed [9]. Furthermore, quantitative *in situ* measurement of ER mRNA predicts response to endocrine therapy.

Classification of breast cancer by immunohistochemical expression of estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2 (HER2) [10] and Ki-67 (protein) is standard practice for clinical decision-making [11].

Ki-67 is an excellent cellular marker for proliferation which determines the growth fraction of a given cell population. The fraction of Ki-67-positive tumor cells is often correlated with the clinical course of breast (and other) cancers. In breast cancer, a result of <10% is considered low, 10-20% borderline, and a result of >20% is considered high. Among others, Ki-67 is included in the prognostic factors of overall survival in patients with early hormone receptor-positive invasive ductal breast carcinoma [12]. In addition, high levels of HER2 expression identify those women who benefit from treatment with agents that target HER2. However, HER2 positivity may be associated with resistance to endocrine therapies [10].

It seems that inherited or external factors can influence the percentage of ER-positive tumors. As an example, patients with ≥ 2 full-term pregnancies exhibit higher percentage of ER-positive tumors, compared with patients who experienced <2 times full-term pregnancies. Similarly, patients whose age of menarche was ≥ 15 years exhibited a greater chance of PR-positive tumors compared with those whose age of menarche was <15 years old [13].

Several meta-analyses have demonstrated that endocrine therapy consistently improves prognosis (survival outcomes) for women with (non-metastatic) HR-positive breast cancer. Starting a few decades ago [14], the selective estrogen

Cyclin E and its Potential Use for Liver Cancer Prognosis and Therapy

Nikki P. Lee^{1,2,*}

¹ Department of Surgery, The University of Hong Kong, Hong Kong, China

² Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Zhejiang University, 310003 Hangzhou, China

Abstract: Liver cancer is an aggressive malignancy developed in the liver. Hepatocellular carcinoma (HCC) is the predominant form of liver cancer worldwide. The prognosis of HCC patients remains poor even with the evolving development on technologies for disease diagnosis, prognosis and treatment. New methods to improve the management of HCC patients should be implemented. Cell cycle deregulation is one key mechanism leading to HCC. Cyclin E is a cell cycle molecule regulating G1 to S phase transition of the cell cycle. The prominent cell cycle regulating function of cyclin E has signified its involvement in HCC when its activity is deregulated. This chapter summarizes the current research on cyclin E in HCC and with a special focus on its underlying, well-studied downstream mechanism involving retinoblastoma-E2F transcriptional factor network. Lastly, research on the potential use of cyclin E for HCC prognosis and treatment is also highlighted and discussed.

Keywords: Cell cycle, Cyclin E, Cyclin E1, Cyclin E2, Cyclin-dependent kinase 2, Drug, E2F, Liver cancer, Marker, Overexpression, Prognosis, Retinoblastoma, Therapy, Treatment, Tumorigenesis.

LIMITATIONS OF CURRENT LIVER CANCER MANAGEMENT

Liver cancer is a global liver disease coupled with high mortality. Each year, more than half a million new cases appear and burden heavily on the healthcare system

* Corresponding author Nikki P. Lee: Department of Surgery, The University of Hong Kong, Faculty of Medicine Building, 21 Sassoon Road, Pokfulam, Hong Kong; Tel: 852-39179652; Fax: 852-39179634; Email: nikkilee@hku.hk

(GLOBOCAN 2012). Hepatocellular carcinoma (HCC) is the predominant type of liver cancer, contributing up to more than 80% of the total liver cancer incidences. The management of HCC is clinically demanding especially for the late diagnosed patients who are in advanced disease stage. Late diagnosis is common in HCC due to the asymptomatic nature of the liver tumor. This situation is further compounded by the suboptimal performance of current screening methods including ultrasonography and serum alpha-fetoprotein (AFP) test. For very early and early stage patients, curative resection including tumor resection and liver transplantation remains the frontline treatments. However, these treatments are not suitable for late stage patients and those with metastatic or unresectable tumors. These patients instead are treated alternatively with transarterial chemoembolization, radiofrequency ablation, alcohol injection, molecular targeting therapy, *e.g.* sorafenib and others [1 - 3]. Even with this wide range of treatment options, not all patients can achieve complete cure. Under this clinical situation, it is a long-term goal to research for new strategies to improve the management of HCC in the areas of diagnosis, prognosis and treatment.

Deregulation of Cell Cycle in Tumorigenesis

Cell cycle is a cellular process that generates new daughter cells when a mother cell completes the cell cycle by passing through four phases from G1, S, G2 to M phase. Each phase of the cell cycle represents a preparative stage for the mother cell to acquire essential cellular machinery before the final step of cell division to generate daughter cells. During each cell division, the genetic stability of the daughter cells is tightly maintained and safeguarded by the presence of a distinct set of cell cycle checkpoints. There are four main types of cell cycle checkpoint, composing of G1/S checkpoint, intra-S checkpoint, G2/M checkpoint and spindle assembly checkpoint [4, 5]. In response to any damages or errors occurred during cell cycling, these checkpoints will be activated to halt the progressing cell cycle, such that the damages or errors can be properly repaired before cells entering the next phase of the cell cycle [5, 6]. The presence of this checkpoint mechanism can maintain the genome stability of the dividing cells.

Fine control on cell cycle can sustain physiological processes of cell growth, development and reproduction. Deregulation of cell cycle control, however,

triggers a wide range of diseases in particular cancers. In various types of cancers including HCC, rapid cell cycling coupled with uncontrolled proliferation and multiplication of cancer cells is a hallmark event in tumorigenesis. For HCC, cancer cells lacking control on cell cycle can lead to the formation of tumor nodules in the liver. It is obvious that deregulation of cell cycle in cancer cells belongs to a signature event of liver tumorigenesis. Although it remains unknown whether cancer cell cycle is resulted from failure to control cell cycle or is due to the action of a specific set of cancer-associated cell cycle regulators, a number of studies have reported the involvement of several cell cycle molecules in tumorigenesis. Cell cycle molecules regulating G1 to S phase transition of the cell cycle is frequently found deregulated in tumorigenesis of different types, including lung, breast, head and neck, glioma, pancreas and liver [7]. This observation further implicates the potential use of detecting and controlling cancer cell cycle for diagnosis, prognosis and treatment of HCC.

Cyclin E, A Cell Cycle Molecule Regulating G1 to S Phase Transition

Cyclin E is a key cell cycle molecule regulating G1 to S phase transition of the cell cycle [7, 8] (Fig. 1). The expression of cyclin E is mainly regulated at the transcriptional level and at the post-translational level [8]. Cyclin E performs its cell cycle-regulating function *via* binding to and activating a protein kinase known as cyclin-dependent kinase 2. Upon binding with cyclin E, cyclin-dependent kinase 2 will phosphorylate a plethora of protein substrates responsible for entry into S phase of the cell cycle. Examples of these substrates are retinoblastoma, nucleophosmin, proliferating cell nuclear antigen and c-Myc. These substrates have immediate roles on cell cycle progression by mediating centrosome duplication, modulating DNA replication and turning on cell cycle-related transcriptional program [8 - 10]. Some of them are indeed tumorigenic molecules themselves, such that their deregulations can also lead to detrimental effects frequently observed during tumorigenesis [10].

Cyclin E has an indispensable role on propagating the cell cycle *via* its effect on regulating the G1 to S phase transition, *i.e.* passing the G1/S checkpoint. Two studies on HCC have confirmed the regulatory role of cyclin E on this aspect. Tsuji *et al.* have revealed higher cyclin E level in cultured HCC cells expressing

SUBJECT INDEX

- 2-Deoxyglucose 131
3-Bromopyruvate 131
- A**
- Acquired resistance 120, 121, 127
Activation of 3, 45, 56, 133
 invasion 3, 45, 56
 invasion and metastasis 45, 56
 metastasis 3
 PDC 133
Active symptom control (ASC) 61
Acute respiratory distress syndrome (ARDS)
 42
ADCC activity 48
Adenocarcinoma 19, 20, 97, 176, 179, 181, 182
 pancreatic 176, 179, 181, 182
Adenomas 98, 99, 100, 117, 126
Adenomatous polyposis coli (APC) 61, 98, 101
Adjuvant 28, 102, 106, 182, 183, 201, 205, 211,
 213, 214, 219, 220
 AIs 213
 chemotherapy 102, 106, 214, 219
 tamoxifen 205, 211, 214, 220
 therapy 28, 182, 183, 205
 Tx 201
Advanced pancreatic cancer 183, 184, 191,
 192, 193
Agents 48, 50, 51, 53, 54, 59, 61, 62, 63, 102,
 103, 107, 108, 109, 110, 111, 112, 118,
 131, 133, 178, 180, 183, 187, 188, 190,
 191, 192, 203, 206, 237
 anticancer 109, 110, 131, 133, 178
 anti-cancer 108, 206
 antitumor 62
 anti-tumor 108
 cytotoxic 102, 187
 natural antitumor 108
 novel 112, 188, 190
 single 48, 50, 51, 59, 118, 183
 targeted 54, 63, 102, 111, 112
 vascular disrupting 53
Aggressive tumors 4, 31
Amatuximab 57, 192
American joint committee on cancer (AJCC)
 181, 182
American society of clinical oncology (ASCO)
 205, 211
Amphibole fibers 5
Analysis, multivariate 29, 33, 35
Anastrozole 201, 202, 212, 215, 216, 217, 218,
 219, 220
 doses of 216, 217
 Anastrozole users 219
Anemia 185, 210
Angiogenesis 33, 39, 48, 52, 53, 54, 97, 114,
 117, 120, 124, 125, 174, 189, 234
 tumoral 33
 Angiogenesis 3, 180, 189
 induction 3
 inhibitors 180, 189
Anti-EGFR therapies 120, 121, 134
Antisense oligonucleotide 115, 127
Antitumor activity 54, 63, 121
Anti-tumor activity 50, 103, 191
 potent 192
Antitumor activity 119, 189
 robust 189
Antitumor effects 48, 190
Anti-tumorigenesis 238
APC mutations 98, 99
Apoptosis 32, 33, 34, 58, 59, 62, 63, 100, 101,
 109, 110, 115, 116, 117, 126, 130
 acetate-induced 130
Appetite loss 28, 29, 215
Arginine 63, 64
Aromatase 204, 212
Aromatase inhibitors 201, 202, 204, 205, 212,
 213, 215, 220
 recognized side effects of 212, 213
Aromatase inhibitors (AIs) 201, 202, 204, 206,
 212, 213, 214, 215, 220
Asbestos 4, 5, 6, 7, 8, 9, 12, 13, 14, 23, 24, 28,
 29, 30, 37, 58, 67
 blue 5
 exposure 6, 9, 23, 24, 28, 37, 67
 fibers 5, 8, 9, 58
 -related disease (ARD) 8
Ascorbate 135

ATP-binding site 114, 121, 122
Atrial fibrillation 216, 219
Autophagy 96, 129, 178, 179, 218

B

Base excision repair (BER) 104
B-catenin 98, 99, 178, 180
BC mortality 201
Bevacizumab 51, 53, 54, 94, 115, 125
Biological compatibility 139
Biological process 113, 114, 115
Biopsy 15, 16, 25, 26, 41, 210
 endometrial 210
 open 16
 pleural 15, 16
Body mass index (BMI) 38
Bolus injections 103, 104, 109
Bone density 217, 218
Bortezomib 59
BRAF oncogenes 98, 99
Breast cancer 23, 47, 94, 136, 201, 202, 203,
 204, 205, 209, 211, 212, 213, 217, 220
 endocrine-responsive early 217
 estrogen-receptor-positive 202
 high-risk 211
 hormone-receptor-negative 202
 positive 201, 202, 204, 205, 220
 receptor-positive 202
 vast majority of 202
Breast cancers (BCs) 201, 202, 204, 205, 207,
 212, 214, 215, 217, 220
 mortality 204, 205, 220
 patients candidates 214
 prevention trial 207
 recurrence 215, 217
 survival 215
Breast carcinoma 20
British thoracic society (BTS) 14
Bronchopleural fistula 42

C

Calretinin 19, 20, 21, 26, 65
Camptothecin 108, 109
Cancer and leukemia group B (CALGB) 28, 29
Cancer Care Ontario (CCO) 211

Cancer cell cycle 230, 238
Cancer cell proliferation 58, 94, 96
Cancer cells 45, 46, 55, 56, 105, 106, 128, 129,
 130, 131, 132, 134, 135, 230, 232, 236,
 237
 breast 232, 236, 237
 esophageal 236
 liver 232
 targeting 237
Cancer cells 53, 130, 136
 proliferation 53, 130
 survival 136
 use 130
Cancer pathways 177, 178
 functional 177
Cancer(s) 3, 8, 13, 23, 29, 45, 48, 49, 50, 52,
 53, 56, 57, 61, 66, 67, 94, 95, 96, 98, 102,
 103, 107, 108, 109, 112, 117, 123, 127,
 128, 129, 131, 132, 133, 134, 136, 137,
 140, 141, 192, 229, 230, 232, 235, 237
 colon 47, 96, 98, 123
 frequent 94
 hallmarks of 45, 94, 127
 liver 228, 229, 232, 235
 metastatic 13, 117
 ovarian 8, 192
 prostate 50, 94
 therapy 3, 61, 67, 94, 102, 103, 108, 109,
 112, 128, 140
 treatment 66, 131, 132, 133, 136, 137
 types 95, 134, 141
Capecitabine 186, 188
Carbohydrates 142
Carbon nanotubes 6, 7, 139
Carboplatin 27, 39, 110
Carcinomas 14, 17, 18, 20, 21, 23, 25, 54, 116,
 117, 122, 125, 126, 133, 209, 210, 228,
 229
 colorectal 116, 117, 122, 125, 126
 endometrial 209, 210
 hepatocellular 23, 133, 228, 229
 metastatic 17, 18, 20
Cardiovascular system 208
Caspases 126, 127, 190
CDK inhibitors 33
Celiac axis 181, 182
Cell carcinoma, transitional 21

- Cell cycle 10, 11, 32, 33, 55, 62, 109, 110, 118, 120, 189, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237
targeting cancer 237
arrest 32, 55, 62, 109, 118, 120
checkpoints 229, 231
deregulation 228, 229, 230
inhibitor 236
molecules 228, 230, 231, 235, 236, 237
molecules cancer-associated 237
progression 47, 116, 230
regulator Cyclin D1 189
regulators, cancer-associated 230
- Cell cycling 229, 230, 231, 232, 237
rapid 230, 232
uncontrolled 231
- Cells 17, 34, 46, 53, 58, 62, 65, 97, 104, 106, 110, 119, 126, 127, 129, 135, 140, 143, 178, 179, 180, 229, 230, 237
dendritic 65
immune 53, 180
inflammatory 58, 179
mother 229
normal 129, 135, 143, 237
stem 62, 180
tumor-associated 46
tumorigenic 119, 180
- Cells survival 58
- Cellular 105, 106, 134, 135, 178
ability 105, 106
membranes 134, 135
metabolism in pancreatic cancer 178
- Cetuximab 47, 48, 49, 93, 94, 113, 118, 119, 120
treatment 118, 120
- Chemotherapeutic agents 34, 102, 106, 118, 120
classical 102
- Chest pain 27, 28, 29, 37
- Chest wall 12, 13, 26, 29, 36, 39, 40, 43
- Chromosomal arms 9
- Chromosomal instability 98, 101
- Chromosome 31, 32, 56, 99, 100, 116
- Chrysotile 5
- Classical chemotherapy 94, 112, 125
- Classification 181
tumor–node–metastasis 181
- Clinical benefit response 184, 186
- Clinicopathological staging 35, 36
- Colloidal carriers 140
- Colon carcinogenesis 93, 95, 100
- Colonocytes 128
- Colorectal cancer 53, 93, 94, 96, 99, 100, 101, 102, 112, 120, 125, 127, 130, 131, 132, 133, 135, 136, 137, 140, 143, 187
metastatic 53, 100
targeted nanoparticles 140
therapy 102, 112, 127, 131, 135, 136, 137
- Colorectal carcinoma progression 122, 123
- Combination regimen 183
chemotherapeutic 183
- Components, epithelial 21, 26
- Compounds, platinum-based 109, 110
- Computed tomography (CT) 13, 16, 26, 27, 30, 38, 51, 181
- Concentration, intratumoral gemcitabine 189
- Congenital anomalies 216, 217, 219
- Constitutive activation 46, 99, 100
- Counter action target Drug 57
- Cowpea mosaic virus 139
- CRC 93, 94, 95, 96, 97, 98, 99, 100, 101, 117, 121, 128, 130, 134, 143
risk of 95, 128
sporadic 98, 99
- CRC carcinogenesis 98, 100
- CRC cells apoptosis 96
- CRC cell survival in response to acetate 96, 130
- CRC development 97, 98, 99, 101, 124
- CRC therapy 102, 108, 111, 112, 134, 137, 138, 142, 143
- CRC tumors 100
- Crocidolite 5
- Cryotherapy 3, 66
- Cyclin 9, 10, 33, 230, 233, 234, 235, 236, 237
-dependent kinase inhibitor proteins 10
dependent kinases (CDKs) 9, 33
deregulation of 235
downstream mechanism of 233, 234
expression of 230, 235, 236
overexpression of 235, 236
prognostic value of 235
suppressing 234, 237
targeting 237
- Cytokeratin 20, 21, 26
- Cytotoxicity 7, 108, 110, 131
- Cytotoxic T-lymphocyte antigen 59, 60

D

Dasatinib 48, 51
 Defactinib 62
 Dendrimers 137, 138
 Dendritic cells vaccine 3, 65
 Deoxythymidine monophosphate 103
 Deregulating cellular metabolism 3, 63
 Deregulation of cell cycle in tumorigenesis 229
 Desmoplastic reaction 179
 Diagnosis 22, 23, 25, 67
 definitive 25
 early 22, 23, 67
 Diagram of multi-step tumorigenesis
 mesothelioma 12
 Diaphragmatic resection 43
 Diarrhea 106, 109, 111, 188
 Dichloroacetate 133
 Disease progression 43, 103
 DNA, alkylates 185
 Downregulation 32, 34, 55, 58, 59, 119, 235
 Dyspnea 28, 29, 210

E

Effects 54, 103, 109, 111, 112, 132, 236, 237
 antiangiogenic 54
 anti-tumor 236, 237
 secondary 103, 109, 111, 112, 132
 Effusion cytology 25
 EGFR 47, 48, 49, 50, 117, 118, 119, 121, 123
 extracellular domain of 47, 118
 binding site 119
 expression 49, 117
 inhibition 50, 121, 123
 inhibitors 47, 48, 49, 117
 Empyema 14, 42
 Enabling replicative immortality 3, 45, 56
 Endocrine therapy 202, 203, 204, 205, 212,
 213, 219
 Endometrial 206, 209
 cancer 206, 209
 polyps 209
 Endothelial cells 53, 125, 192
 Energy production 178, 179
 Enhanced permeability and retention (EPR)
 140

Environment, extracellular 130, 132
 Enzastaurin 52
 Epidermal growth factor (EGF) 11, 23, 33, 46,
 47, 93, 115, 142, 174, 185, 203
 Epidermal growth factor receptor (EGFR) 46,
 47, 49, 93, 98, 99, 113, 115, 117, 118,
 119, 120, 121, 122, 123
 Epithelial membrane antigen (EMA) 19, 20, 22
 EPR effect 141
 Erlotinib 48, 93, 113, 119, 174, 183, 184, 185,
 186, 188
 ER-positive breast cancer 204, 212, 218
 ER-positive breast cancer in postmenopausal
 women 216, 217, 218
 ER-positive tumors 203
 Esophagus 35, 40, 42
 Estrogen production 201, 204, 212, 213
 Estrogens 212, 214, 217, 218
 Estrone 217, 218
 Estrone sulfate 217, 218
 Evading growth suppressors 3, 45, 55
 Everolimus 62, 114, 122
 Exemestane 201, 202, 211, 212, 213, 214, 215,
 216, 217, 218, 219, 220
 doses of 218
 Exonucleases 105
 Exosome 105
 Expression, tumor IGF-IR 50
 Extracellular domain 113, 115, 117, 119, 123
 Extracellular regulated kinase (ERK) 32, 116,
 189
 Extrapleural pneumonectomy 16, 31, 40, 41

F

Factors 53, 64, 93, 95, 116, 118, 124, 127, 189,
 233, 235
 hereditary 93, 95
 immunosuppressive 64
 pro-angiogenic 118, 124
 transcriptional 116, 233, 235
 tumor-growth 189
 tumor necrosis 53, 127
 Familial adenomatous polyposis (FAP) 95, 96,
 98
 Family 127
 tumor necrosis factor receptor 127

- Fibroblast growth factor receptor (FGFR) 50, 190
 Fibroblasts 179, 181
 Fibulin-3 23
 Fine needle aspiration (FNA) 15, 16
 Fine needle aspiration cytology (FNAC) 16
 Fluorescence *in-situ* hybridization (FISH) 10, 31
 Fluoro-edenite 6
 Fluorouracil 182, 183, 184, 186, 187
 Focal adhesion kinase (FAK) 62, 190
 Full-term pregnancies 203
 Functions, regulatory 55, 231, 232
- G**
- Gastrointestinal tract 22, 217, 218
 Gemcitabine 38, 57, 180, 182, 183, 184, 185, 186, 187, 189, 190, 191, 192, 193
 chemotherapeutic agent 180
 Gemcitabine combination 184
 Gene expression changes 11
 Gene mutations 98, 189
 Genetic mutations 177
 Genitourinary system 208, 209, 215
 Genome instability 3, 61
 Gliomas 136, 230
 Glucose 128, 130, 131, 132, 134, 178
 phosphorylation of 132
 transporters 130, 131, 134
 uptake 134
 Glycolysis 34, 128, 130, 131, 132, 178
 Glycolytic metabolism 133, 134, 135
 GnRH analogues 201, 202, 213, 214, 220
 Growth factor receptors 11, 46, 50, 93, 115, 121, 185, 190, 193
 epidermal 11, 46, 93, 115, 185
 fibroblast 50, 190
 Growth factors 11, 32, 33, 46, 48, 49, 52, 54, 122, 123, 124, 140, 174, 179, 233
 vascular endothelial 33, 48, 52, 124, 179
- H**
- Hallmarks of cancer and targeted treatment in MPM 49, 57
 Hand-foot syndrome 188
- HCC 228, 229, 230, 231, 234, 235, 236, 237
 management of 229
 HCC cells 231, 234, 236
 cyclin E-suppressed 236
 HDAC inhibitors 63
 Hedgehog signaling pathway 180, 188, 189
 Hepatocyte growth factor (HGF) 11, 56
 High density lipoprotein (HDL) 215, 218
 High tumor grade 201, 213, 214
 Histologic subtyping 18
 Histone 62, 129
 acetyltransferases (HATs) 129
 deacetylase 62, 129
 Homozygous deletions 32, 55
 HR-positive breast cancer 203, 205, 211, 212
 Hyaluronic acid 14, 179
 Hypovascularity and fibrotic microenvironment in pancreatic cancer 178
- I**
- IFL regimen 109
 Ig domain 125
 Imaging tests 13, 14, 15, 16
 Immune destruction 3, 57, 59, 60
 Immune response 33, 45, 64, 65, 118
 Immunohistochemistry 18, 21, 26, 52, 118, 121, 235
 Immunomodulation in pancreatic cancer 180
 Immunomodulatory drugs 53, 54
 Immunotherapy 4, 64, 65
 Incidence of endometrial cancer 206, 209
 Incidence of pancreatic cancer 175
 Infiltration, tumoral 43
 Infusion 184, 185, 187
 fixed-dose 185
 Intracellular domain 47, 115, 118, 123
 Intracellular levels 106, 107
 Intraoperative hyperthermic chemotherapy 3, 39
 Intravasation of cancer cells 56
 Inulin-type fructans (ITF) 128, 129
 Invasion 25, 26
 lymphovascular 201, 213, 214
 tissue 25, 26, 201, 213, 214
 Invasive CRC 98, 100
 Involvement, lymph node 26, 35, 36

Iodine-povidone lavage 3, 66
Ipsilateral involvement 37

K

Ki-67-positive tumor cells 203
Kinase 50, 119, 125, 228, 230, 232, 233
 cyclin-dependent 228, 230, 232, 233
 domain, tyrosine 50, 119, 125
KRAS activation and deletion of tumor
suppressor genes 176

L

Lactate 31, 130, 132
Letrozole 202, 212, 215, 216, 217, 218, 220
Leucovorin 93, 106, 183, 186, 187
Ligands 34, 39, 47, 49, 50, 59, 60, 99, 110, 115,
 117, 118, 120, 126, 138, 140, 142, 143,
 180, 188
 cell inhibitory 59, 60
 natural 115, 117, 118, 120
 targeting 138, 142
 tumor-related apoptosis-inducing 34
Liver tumorigenesis 230, 236
 counteract 236
Low molecular weight cyclin 232, 233
Lung adenocarcinoma 19
Lung cancer 5, 22, 23, 26, 29
Lymph nodes 36, 101, 201, 213, 214
Lysosome membrane permeabilization (LMP)
 96, 130

M

Macrophages 9, 59, 64, 139, 141, 179
Magnetic resonance image (MRI) 13, 25, 26
Malignant cells 14, 189
Malignant mesothelioma 8, 9, 11, 14, 18, 21,
 22, 26, 53
 pleural 11
Malignant tumor 15, 22, 101, 125
Markers 20, 25, 26, 189
 cancer stromal cells 189
 mesothelial 20, 25, 26
Masitinib 190
Massive cancer cell apoptosis, induced 191

MCTs, cancer cells overexpress 135
Median survival in advanced pancreatic cancer
 184
Mesenteric artery, superior 181, 182
Mesothelial cells 4, 8, 9, 10, 14, 18, 22, 31
 benign 14, 22
 malignant 10, 22
Mesothelial tumors 17
Mesothelin 3, 20, 22, 23, 39, 57, 65, 66, 192
 soluble 22, 23
Mesothelioma 5, 6, 7, 14, 15, 17, 18, 19, 20, 21,
 22, 23, 26, 27, 44, 50, 65
 epithelioid 18, 21, 22
 peritoneal 5, 7
Mesothelioma patients base don survival 36
Metabolic alterations 95, 130
Metabolic targets 94
Metabolites, active 207
Metastasis 25, 102, 181, 182
 distant 25, 181, 182
 microscopic 102
Metastatic disease 12, 15, 36, 38, 183
Methylenetetrahydrofolate 103, 104, 106, 107
 concentrations 106
 polyglutamylated forms of 107
Microsatellite instability 95, 98, 101
Minithoracotomy 16
Mitogen-activated protein kinase (MAPK) 32,
 116, 191, 193
Molecular biology of pancreatic cancer 176
Molecular pathway 32
Molecular targets 142, 143
Molecules TK inhibitors 113, 123
Monoclonal antibodies 19, 20, 53, 60, 113, 117,
 118, 119, 123, 190, 191, 192, 193
 humanized IgG1 113
Monoclonal antibody anti-IGF1R 113
Monotherapy 38, 39, 49, 118, 201, 204, 213
MTOR inhibitor temsirolimus 54
Multifactorial disease process 93, 95
Multi-step tumorigenesis mesothelioma 12
Mutated KRAS 99, 120, 134, 135, 177
Mutation cluster region (MCR) 99
Mutations 10, 11, 48, 96, 98, 177
 activating 11, 48, 177
 germline 96, 98
 inactivating 10, 177
MUTYH-associated polyposis (MAP) 96, 191

Myeloid derived suppressor cells (MDSCs) 64

N

Nanoparticles 6, 94, 136, 137, 138, 139, 140, 141, 142, 143, 187

gold 137, 139

in colorectal cancer therapy 137

polymeric 137, 138

transport of classical drugs by 94, 137

viral 137, 139

Natural killers (NK) 9, 118

Nausea constipation diarrhea 215

Next-generation sequencing (NGS) 61

Nivolumab 57, 60, 61

Nonepitheloid 28

O

Oestrone 212

Oophorectomy 211

Oral contraception 206, 207

Origin of Pancreatic Cancer Cells 176

Osteopenia 212, 213

Osteoporosis 211, 212, 213, 215, 216, 218

self-reported new diagnoses of 216, 218

Ovarian ablation 211

Ovarian function 209, 210, 211, 214

Ovarian function suppression 214

Ovarian irradiation 211, 214

Ovarian suppression 201, 210, 211, 212, 213, 220

Overexpression WB 235

P

Pancreas 181, 182, 187, 230

Pancreatectomy 181, 182

Pancreatic cancer 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 187, 190, 191, 192, 193

biology 193

cells 176, 178, 179, 190, 191

components 179

curable 175

genetics 177

growth 179, 193

human 191

inoperable 190

management of 174, 182, 183

metastatic 184, 187

microenvironment 180

resectable 183

staging 181

stem cells (PCSC) 179, 180

stroma 179

therapies 193

treatment of 174, 183, 193

unresectable 177, 183

untreated metastatic 192

Pancreatic tumor cells 178

Panitumumab 93, 94, 113, 119, 120, 143

Parietal pleura 4, 17, 36, 41, 43

Pathways 34, 126, 127, 188

extrinsic 34, 126, 127

hedgehog 188

PD-L1 expression 60

Pembrolizumab 60, 61

Pericardial patch dehiscence 42

Pericardium 4, 31, 35, 36, 43

Photodynamic therapy 3, 66

Physical properties, unique 140

Platelet count 28, 29

Platelet-derived growth factor (PDGF) 33, 48, 124, 179, 190

Pleura 4, 9, 12, 13, 15, 16, 18, 36, 43

visceral 4, 12, 16, 36, 43

Pleural cavity 16, 27, 42

Pleural effusion 9, 12, 13, 14, 16, 22, 23, 25, 26, 40, 44, 65

large 16

Pleural fluid cytology 14

Pleural space 16, 17, 43

Pleural tumors 10, 15

Pleurectomy 40, 41

Pleurectomy/decortication 41, 44, 66

Pleurodesis 14, 27, 44

thoracoscopic 27

Podoplanin 19, 20, 22, 26

Postmenopausal women 201, 204, 205, 206, 209, 212, 214, 216, 217, 218, 220

Post-translational level 230, 232

Potential risk of miscarriage 216, 217, 219

Premenopausal women 201, 204, 205, 210, 211, 213, 214

Prognosis 3, 4, 11, 18, 30, 31, 33, 34, 44, 45, 202, 203, 228, 229, 230
Prognostic factors 13, 27, 29, 30, 31, 32, 33, 203
 favourable 27
 unfavourable 27
Programmed deaths 34, 59, 60, 193
Progression-free survival (PFS) 54, 59, 184, 185, 186, 187, 192
Proliferation, cancer cells BaF3 129
Proliferative signaling 4, 45, 46
Property, strong anti-tumorigenic 94, 96
Proteins 32, 33, 46, 47, 61, 62, 98, 100, 101, 105, 106, 120, 121, 126, 127, 179, 188
 anti-apoptotic 126, 127
Protein tyrosine kinase (PTKs) 48
Pulmonary toxicity 40, 41, 49

Q

Quantum dots (QDs) 137, 139

R

Radiotherapy 3, 27, 38, 39, 40, 43, 44, 102, 125, 131
RAF proteins inhibitors 114, 121
Rapamycin 114, 116, 122
Ras-dependent tumor proliferation 191
RAS proteins 116
Reactive oxygen species (ROS) 135, 178
Receptors 22, 33, 47, 48, 52, 56, 57, 59, 60, 61, 99, 115, 118, 120, 122, 123, 127, 201, 202, 203, 220
 estrogen 22, 201, 202, 203
 hormone 201, 202, 220
 inhibitory cell surface 52
 tumor necrosis factor 127
Receptor tyrosine kinase (RTKs) 11, 49, 50
Regimen 51, 52, 59, 95, 96, 107, 109, 111, 112, 183, 184, 185, 187, 189
 combined 107, 109, 112
 dietary 95, 96
 multi-agent 183
 optimal 107
Regorafenib 114, 125
Regulating G1 228, 230

Relapses 102
Resisting cell death 3, 45, 58
Retinoblastoma 228, 230, 233
 initial phosphorylation of 233
Retinoblastoma-E2F transcriptional factor network 228, 233, 234
RNA metabolism 104, 105
RRNA processing 105

S

Salirasib 191
Sarcomatoid 15, 17, 18, 21, 25, 26, 30, 60
Sarcomatoid mesotheliomas 10, 14, 19, 21, 22, 26
Sarcomatoid subtype 21, 30, 32, 61
Selected altered genes 177, 178
Serum estradiol 216, 217, 218
Short-chain fatty acids (SCFAs) 94, 95, 96, 128, 129
Signaling pathways, downstream 46, 115, 117, 118, 120, 123
Solid Tumor 7, 51, 53, 109, 141
Soluble mesothelin-related proteins (SMRP) 13, 26, 38
Sorafenib 50, 51, 52, 114, 121, 229
Staging systems 31, 35
Staining intensity 202, 203
Standard uptake value (SUV) 13, 30
Stroke 42, 208, 216, 219
Sunitinib 50, 51
Suppression of serum estradiol 216, 217, 218
Surgery 26, 27, 64
 cytoreductive 27, 64
 radical 26
Surgical resection 40, 44, 182, 183
Survival 30, 31, 32, 33, 35, 40, 41, 48, 49, 50, 51, 59, 109, 111, 181, 183, 184, 185, 186, 187, 189, 190, 211, 212, 213, 214
5-year 181
 disease-free 211, 212
 free 109, 111, 214
 improved 50, 189, 213
 progression-free 59, 184, 185, 186, 187
Survival outcomes 27, 203
Survival rate 13, 29, 60, 187, 192, 193
Survival time 103, 109, 111, 192

- progression-free 192
 - Sustain cell cycling 231
 - Systems 29, 35, 36, 58, 59, 64, 111, 119, 137, 142, 202, 208, 209, 215
 - gastrointestinal 208, 209, 215
 - immune 58, 59, 64, 119
 - nervous 208, 209, 215
- T**
- Tamoxifen 201, 202, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 219, 220
 - effects of 206, 209
 - receiving 206, 207
 - side effects of 207, 210
 - side-effects of 208, 209, 210
 - taking 206, 207, 209, 210
 - Tamoxifen and exemestane trial 214
 - Tamoxifen therapy 204, 206, 208, 209
 - prolonging 206, 208, 209
 - Tamoxifen treatment 205, 206, 207, 212
 - Tamoxifen users 209, 210
 - Targeted therapies 67, 102, 111, 112, 141
 - Target genes 188, 233, 234
 - Targeting pancreatic cancer stroma 179
 - Targeting tumor cells 65
 - Target therapy 94, 131
 - Task cancer cells overexpress monocarboxylate transporters 130
 - T-cell-mediated anti-tumor immunity mechanisms 180
 - Telomerase 56
 - Temsirolimus 54, 122
 - Thalidomide 53, 54
 - Therapeutic agents 103, 134, 137, 138, 187
 - Therapeutic targets 45, 56, 61, 62, 178
 - Therapies 113, 206, 207
 - hormone replacement 206, 207
 - single 113
 - Thoracocentesis 14
 - Thoracotomy 15, 17, 44
 - Thorotrast 7
 - Thrombocytopenia 185, 186, 210
 - Thrombocytosis 12
 - Thromboembolic events 13, 206, 207, 208
 - Thrombosis 206
 - Thymidilate synthetase 186, 187
 - Thymidylate synthase (TS) 103, 104, 106, 107
 - Tissues 7, 15, 26, 33, 45, 64, 101, 117, 124, 127, 128, 129, 130, 131, 132, 138, 140, 190, 204, 211, 212, 232
 - non-tumor 190, 232
 - normal 33, 45, 117, 127, 130, 131, 132, 211
 - Tivantinib 57
 - TNFRade 192
 - Topoisomerase 186, 187
 - TP53 gene 32, 55, 100, 177
 - Transcription 62, 100, 108, 109, 180, 188, 233
 - Tremelimumab 57, 60
 - Tuberculosis 8, 14
 - Tuberculous pleurisy 13, 14
 - Tumor activity 136
 - Tumoral cells 64
 - Tumor angiogenesis 189
 - Tumor cells 39, 46, 49, 52, 55, 56, 60, 64, 122, 129, 130, 137, 180, 187, 190, 192
 - susceptible 190
 - Tumor formation 59, 179
 - Tumor growth 32, 45, 52, 58, 62, 120, 124, 136, 179, 191
 - Tumorigenesis 50, 62, 180, 228, 229, 230, 231, 232, 233, 234, 237
 - counteract 237
 - Tumor invasion 56, 130
 - Tumor invasiveness 14, 47, 235
 - tumor thrombus 235
 - Tumor metastasis 235
 - Tumor microenvironment 54, 60, 130, 134
 - Tumor necrosis factor (TNF) 34, 53, 124, 127, 178, 192
 - Tumor necrosis factor- α 192
 - Tumor necrosis factor family 34
 - Tumor-Node-Metastasis 31
 - Tumor phenotypes 234, 236
 - Tumor progression 22, 101, 189, 191
 - Tumor proliferation 192
 - Tumor regression 120, 181, 189
 - Tumor-related apoptosis-inducing ligands (TRAIL) 34, 127
 - Tumor response 107
 - Tumors 17, 18, 21, 38, 40, 43, 44, 45, 56, 110, 127, 141, 176, 177, 180, 181, 182, 183, 192, 229, 232
 - cisplatin-resistant 110
 - expressing 192

metastatic 21, 183
pancreatic 176, 180
unresectable 183, 229
Tumor size, large 213, 214
Tumor stroma 46, 179, 180, 189
Tumor suppression pathways 32
Tumor suppressor genes (TSG) 7, 9, 10, 11, 55, 98, 100, 101, 176
Tumor suppressor genes TP53 176
Tumor suppressor pathway 33
Tumor suppressors 23, 34, 55, 134
Tumor tissue 50, 138, 141
Tumor types 55
Tyrosine kinase (TK) 47, 53, 115, 124, 190
Tyrosine kinase inhibitors (TKIs) 47, 50, 113, 117, 125
Tyrosine kinase receptor (TKR) 98, 99, 124

U

Uracil-DNA glycosylase (UDG) 104
Uracil misincorporation 104

V

Vaccine antigen 65, 66
Vascular endothelial growth factor (VEGF) 11, 33, 48, 50, 51, 52, 54, 113, 114, 115, 124, 125, 140, 142, 179, 234
receptor (VEGFRs) 11, 50, 52, 113, 114, 125
Vatalanib 51, 53, 125
Venous 206, 208, 212
thromboembolism 206
thrombosis 206, 208, 212
Videothoracoscopy 16
Vomiting 106, 110, 111, 185, 187, 188

W

Warburg effect 94, 128, 129
Western blot 235
White blood cell count 28, 29
Wilms tumor antigen 20, 21
World Health Organisation (WHO) 8, 17, 30



PROF. DR. ATTA-UR-RAHMAN, FRS

Atta-ur-Rahman, Ph.D. in organic chemistry from Cambridge University (1968), has 1020 international publications in several fields of organic chemistry including 727 research publications, 37 international patents, 68 chapters in books and 188 books published largely by major U.S. and European presses. He is the Editor-in-Chief of eight European Chemistry journals. He is Editor of the world's leading encyclopedic series of volumes on natural products "Studies in Natural Product Chemistry" 50 volumes of which have been published under his Editorship by Elsevier during the last two decades.

Prof. Rahman won the UNESCO Science Prize (1999) and was elected as Fellow of the prestigious Royal Society (London) in July 2006. He has been conferred honorary doctorate degrees by many universities including (Sc.D.) by the Cambridge University (UK) (1987). He was elected Honorary Life Fellow of Kings College, Cambridge University, UK, conferred the TWAS (Italy) Prize and the Austrian government has honoured him with its high civil award ("Grosse Goldene Ehrenzeischen am Bande") (2007). He is Foreign Fellow of Chinese and Korean Academy of Sciences, Foreign Fellow of the Chinese Chemical Society and former President of Pakistan Academy of Sciences.



PROF. DR. M. IQBAL CHOUDHARY

Dr. M. Iqbal Choudhary is a Professor of Organic/Bioorganic Chemistry and Director at the International Center for Chemical and Biological Sciences (H. E. J. Research Institute of Chemistry and Dr. Panjwani Center for Molecular Medicine and Drug Research). He is among the most prominent scientists of Pakistan, recognized for his original contributions in the fields of natural products and bioorganic chemistry. He has written and edited 27 books, most of which have been published in USA and Europe. He is also the author of over 900 research papers and chapters in top international science journals of the West as well as 27 US patents. The cumulative impact factor of his publication is over 1,650. This is by far the largest number of quality publications from any scientist in Pakistan. He has been among the most cited scientists of Pakistan in last five years with citations exceeding 7,900 (h-Index: 33). He is the Volume Editor of many international book series and journals. He has served as a visiting faculty in many prestigious universities of the world including Cornell University (New York), Purdue University (Indiana), Pennsylvania State University (Pennsylvania), Scripps Institution of Oceanography (San Diego, California), The University Rhode Island (Rhode Island), and various top Universities of UK, Saudi Arabia, Malaysia, Kazakhstan and Iran.